Fusion Antibodies plc announced that it has entered into a commercial contract to develop a bespoke OptiPhageTM library for a non-human antibody species with a leading global provider of antibodies for use in research and diagnostics. OptiPhageTM is Fusion's proprietary phage display platform based on the OptiMAL® library design but in a phage display format. This Contract represents the Company's first commercial sale of its OptiPhage technology and the first commercial library design and supply contract.

It is anticipated that the Project will provide the Client with an alternative pathway to produce high quality antibodies, reducing its need to run animal-based antibody generation. The Client will be able to use the library in its own laboratory to discover antibodies for research use. Whilst the initial fees due to Fusion under the Contract are not themselves material, the Client has also secured an option to an exclusive license to the library for an additional fee and would pay royalties on antibodies developed for diagnostic or therapeutic use.

Fusion remains free to develop further OptiPhageTM libraries for its own use or for other clients as it adds this service to its increasingly comprehensive range of offerings. Phage display is a commonly used discovery method to identify fragments of antibodies which bind to a given target. The fragments are subsequently combined to reconstitute an antibody.

Due to the popularity of the phage display methodology, the board believes that the OptiPhageTM offering represents a significant new opportunity for Fusion to engage with new clients engaged in discovering and developing antibodies for use in research, diagnostics and/or therapeutics. It also creates additional opportunities for the Company to 'upsell' to the more technologically advanced and higher value OptiMAL® platform as well as various protein engineering and supply contracts.